82
Participants
Start Date
December 31, 2011
Primary Completion Date
May 31, 2012
Study Completion Date
May 31, 2012
PF-04991532
Oral administration of PF-04991532; 25 mg given twice a day (BID) for 14 days
PF-04991532
Oral administration of PF-04991532; 75 mg given twice a day (BID) for 14 days
PF-04991532
Oral administration of PF-04991532; 150 mg given twice a day (BID) for 14 days
PF-0499132
Oral administration of PF-04991532; 300 mg given twice a day (BID) for 14 days
Placebo
Oral administration of PF-04991532 Matching Placebo; given twice a day (BID) for 14 days
Pfizer Investigational Site, Miami
Pfizer Investigational Site, Chula Vista
Pfizer Investigational Site, Hachioji-shi
Lead Sponsor
Pfizer
INDUSTRY